Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

Type of Cancer
Lymphoma

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase Ib dose finding study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) plus Lenalidomide/Rituximab in Relapsed or Refractory Mantle Cel Lymphoma (MCL)

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.